Transplant Therapy Procedures Flashcards

I honestly have no idea what else to name this

1
Q

Goals of therapy

A

Suppression of the immune response of recipient to donor transplanted organ
Multiple drug regimen approach employed
Use of multiple drugs with different MoAs
Minimize long-term drug-related drug adverse effects

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What happens if you give too little of a dose?

A

Organ rejection

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What happens if you give too much of a dose?

A

ADEs, infection

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

3 phases of immunosuppressive pharmacotherapy

A

Induction, maintenance, rejection

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Pre-transplant induction therapy

A

Induction agent
IV bolus of methylprednisone sodium succinate
MPA dose

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Days 0-7 post-transplant therapy

A

Few doses of induction agent, then D/C it
IV MEPN changed to PO prednisone with taper
MPA dosing
Low dose CNIs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Maintenance dosing therapy

A

MPA
CNI doses titrated with TDM
Prednisone taper
Monitor allograft function and ADEs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Purpose of induction immunosuppression

A

Prevents organ rejection process from initiating at transplant and immediately on organ placement

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Induction therapy advantages

A

May improve early graft function, prevent rejection, and improve survival

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Induction therapy disadvantages

A

May increase costs and risk of cytomegalovirus infection and post-transplantation lymphoproliferative disease

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What does induction therapy do?

A

Block T-cell activation or other immunologic activation at the time of graft placement

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Induction therapy drugs

A

ATG, ATGAM, IL-2 receptor blocker, alemtuzumab (Campath)

MMF or azathioprine

Glucocorticoids at high doses with rapid taper

Delayed use or low doses of CNIs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Thymoglobulin is what kind of immunosuppression therapy?

A

Depleting induction

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Thymoglobulin dosing

A

IV infusion q4-6h for 2-4 daily doses

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Thymoglobulin MoA

A

Coat the host’s T-cells in the blood and then they get destroyed by complement system

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Thymoglobulin ADEs

A

flu-like syndromes on first dose due to cytokine release syndrome; leukopenia, lymphopenia, thrombocytopenia, pruritus, erythema, serum sickness

17
Q

What can be done to minimize ADEs from thymoglobulin?

A

Premedicate with APAP and diphenhydramine

18
Q

IL-2 receptor blockers

A

Basiliximab (Simulect) and daclizumab (Zenapax)

19
Q

Basiliximab brand name

A

Simulect

20
Q

Daclizumab brand name

A

Zenapax

21
Q

IL-2 receptor blockers MoA

A

Against CD25 which will prevent activated T-lymphocyte proliferation

22
Q

IL-2 receptor blockers ADEs

A

N/V/D

23
Q

What kinds of patients are IL-2 receptor blockers used in?

A

Low-risk patients

24
Q

What kind of immunosuppression therapy are basiliximab and daclizumab?

A

NON-depleting induction therapy

25
Q

Alemtuzumab brand name

A

Campath

26
Q

What kind of immunosuppression therapy is Campath?

A

Depleting induction therapy

27
Q

Campath MoA

A

Directly against the CD52 surface antigen expressed on ALL lymphocytes, NK cells, macrophages, eosinophils, male reproductive system

28
Q

Campath clinical uses

A

B-cell chronic lymphocytic leukemia and MS

Induction agent is an off-label use

29
Q

What kinds of patients is Campath used in?

A

High-risk patients

30
Q

Campath ADEs

A

HAMA reactions, fever, rigors, N/V/D, hypotension, profound lymphopenia and neutropenia, thrombocytopenia, increased risk of malignancy, infection, or autoimmune reactions

31
Q

Campath dosing

A

2 doses or one IV dose over 2-3 hours

32
Q

Purpose of maintenance immunosuppression

A

Achieve a less intense suppression of the immune system over a longer duration

33
Q

Factors to consider for maintenance therapy

A

Deceased or living donors, prior transplants, ADEs, HLA mismatch, number of acute rejections, compliance, drug costs

34
Q

Rejection therapy

A

Management of the immunologic rejection process which can be acute or chronic in order to preserve organ function